SCHEMBL4873394

SCHEMBL4873394

[CH2]/C=C/c1c(F)cc(NC(=O)OC(C)C)cc1F

nearest known ligand 0.44

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
KDM4E B2RXH2 1/20 0.44
HPGD P15428 2/20 0.43
ALOX15 P16050 1/20 0.43
SMN1; SMN2 Q16637 3/20 0.43
NPC1 O15118 2/20 0.43
CYP1A2 P05177 2/20 0.43
CYP2C9 P11712 2/20 0.43
CYP2C19 P33261 2/20 0.43
RAB9A P51151 2/20 0.43
CYP2D6 P10635 1/20 0.43
CASP3 P42574 1/20 0.35
TUBB4A P04350 1/20 0.34
TUBB P07437 1/20 0.34
TUBA3C P0DPH7 1/20 0.34
TUBA1B P68363 1/20 0.34
TUBA4A P68366 1/20 0.34
TUBB4B P68371 1/20 0.34
TUBB3 Q13509 1/20 0.34
TUBB2A Q13885 1/20 0.34
TUBB8 Q3ZCM7 1/20 0.34

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL4879199 0.84 KDM4E (0.43) KDM4EHPGDALOX15SMN1; SMN2NPC1
SCHEMBL4879206 0.84 KDM4E (0.43) KDM4EHPGDALOX15SMN1; SMN2NPC1
SCHEMBL4882291 0.84 KDM4E (0.48) KDM4EHPGDALOX15SMN1; SMN2NPC1
SCHEMBL4875742 0.83 KDM4E (0.43) KDM4EHPGDALOX15SMN1; SMN2NPC1
SCHEMBL5379512 0.83 HPGD (0.44) KDM4EHPGDALOX15SMN1; SMN2NPC1
SCHEMBL4875726 0.83 KDM4E (0.43) KDM4EHPGDALOX15SMN1; SMN2NPC1
SCHEMBL5379521 0.78 KDM4E (0.43) KDM4EHPGDALOX15SMN1; SMN2NPC1
SCHEMBL5379517 0.78 KDM4E (0.43) KDM4EHPGDALOX15SMN1; SMN2NPC1
SCHEMBL6244428 0.76 KDM4E (0.49) KDM4EHPGDALOX15SMN1; SMN2NPC1
SCHEMBL4881032 0.75 KDM4E (0.54) KDM4EHPGDALOX15SMN1; SMN2NPC1

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-20080090884-A1 ANTIMICROBIAL [3.1.0] BICYCLOHEXYLPHENYL- OXAZOLIDINONE DERIVATIVES AND ANALOGUES PFIZER INC 2008-04-17 US disclosed
EP-1615916-A1 ANTIMICROBIAL 3.1.0 BICYCLOHEXYLPHENYL-OXAZOLIDINONE DERIVATIVES AND ANALOGUES Pharmacia & Upjohn Company LLC (US) 2006-01-18 EP disclosed
WO-2004089943-A1 ANTIMICROBIAL [3.1.0] BICYCLOHEXYLPHENYL-OXAZOLIDINONE DERIVATIVES AND ANALOGUES PHARMACIA & UPJOHN COMPANY LLC (US) 2004-10-21 WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20080090884-A1 ANTIMICROBIAL [3.1.0] BICYCLOHEXYLPHENYL- OXAZOLIDINONE DERIVATIVES AND ANALOGUES OXA1L, CYP51A1, CYP2C19 KDM4E 3561/4885HPGD 467/4885ALOX15 2603/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.